ELDN
Eledon Pharmaceuticals, Inc.
Key Financials
Revenue
$0
NaN%
Net Income
$-45617000
↓ 26.1%
Operating Income
$-43000000
↑ 51.4%
EPS (Diluted)
$-0.52
↑ 30.7%
Total Assets
$169.0M
↓ 4.7%
Total Liabilities
$32.2M
↓ 45.6%
Shareholders' Equity
$81.1M
↓ 31.4%
Operating Cash Flow
$-62341000.00
↓ 31.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
| SCHEDULE 13G | 7/31/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| EFFECT | 5/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ELDN |
| Company Name | Eledon Pharmaceuticals, Inc. |
| CIK | 1404281 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 949-238-8090 |